Rxsight Inc RXST.OQ reported a quarterly adjusted loss of 29 cents per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -16 cents. The mean expectation of eleven analysts for the quarter was for a loss of 24 cents per share. Wall Street expected results to range from -33 cents to -15 cents per share.
Revenue fell 3.6% to $33.64 million from a year ago; analysts expected $35.19 million.
Rxsight Inc's reported EPS for the quarter was a loss of 29 cents.
The company reported a quarterly loss of $11.79 million.
Rxsight Inc shares had fallen by 41.9% this quarter and lost 78.0% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 47.7% in the last three months.
In the last 30 days, six analysts negatively revised earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 8 "hold" and 2 "sell" or "strong sell." The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."
Wall Street's median 12-month price target for Rxsight Inc is $9.00, about 13.4% above its last closing price of $7.79
This summary was machine generated from LSEG data August 8 at 04:29 a.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Jun. 30 2025 | -0.24 | -0.29 | Missed |
Mar. 31 2025 | -0.22 | -0.20 | Beat |
Dec. 31 2024 | -0.17 | -0.15 | Beat |
Sep. 30 2024 | -0.25 | -0.16 | Beat |